Anthony Cannon, MD
Endocrinology, Diabetes & Metabolism · Turnersville, NJNPI 1831259340
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $235,836 of the $296,446 with a category attached, or 79.6%. Novo Nordisk accounts for 86.7% of it on its own, with 30 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 559 payments — averaging $530.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$257K
- Abbott$16K
- Johnson & Johnson$7K
- AbbVie$6K
- Medtronic$4K
- Zealand Pharma US, Inc.$2K
- plus $5K from 25 others
What the payments were for
- Consulting fees$2,0401%
- Speaking & faculty fees$235,83680%
- Travel & lodging$41,33514%
- Food & beverage$17,0806%
- Education$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 250 | $257,148 |
| Abbott | 143 | $15,597 |
| Johnson & Johnson | 6 | $6,826 |
| AbbVie | 10 | $6,198 |
| Medtronic(2 entities) | 32 | $3,703 |
| Zealand Pharma US, Inc. | 6 | $2,434 |
| Insulet Corporation | 12 | $553 |
| AstraZeneca | 10 | $491 |
| Bayer | 4 | $354 |
| Sanofi-aventis U.S. LLC | 5 | $311 |
| Lilly USA, LLC | 11 | $282 |
| Boehringer Ingelheim | 6 | $281 |
| Amgen(2 entities) | 7 | $269 |
| Dexcom, Inc. | 5 | $267 |
| Amneal Pharmaceuticals LLC | 15 | $257 |
| Valeritas, Inc. | 4 | $183 |
| Ascendis Pharma Endocrinology Inc | 3 | $148 |
| Cequr Corporation | 3 | $147 |
| BD | 2 | $139 |
| Senseonics, Incorporated | 1 | $125 |
| Corcept Therapeutics | 8 | $125 |
| Mannkind Corporation | 2 | $123 |
| Exelixis Inc. | 1 | $118 |
| Intra-sana Laboratories | 1 | $114 |
| Companion Medical, Inc. | 1 | $86 |
| Xeris Pharmaceuticals, Inc. | 3 | $44 |
| Tandem Diabetes Care, Inc. | 2 | $34 |
| Recordati_rare_diseases_inc. | 2 | $33 |
| Radius Health, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| BETA Bionics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$117,238
- Ozempic$94,440
- Tresiba$19,479
- FREESTYLE LIBRE 3$12,909
- INVOKANA$6,811
- Synthroid$4,550
- Xultophy 100/3.6$4,359
- MINIMED 780G$2,558
- V-GO$1,343
- ZEGALOGUE$800
- V-GO DISPOSABLE INSULIN DELIVERY$415
- Quadra Allure MP RF CRT Pacemkr$291
- Kerendia$250
- FreeStyle Libre 2$248
- FARXIGA$227
- DEXCOM G7 GSS (161)$132
- Eversense$125
- FreeStyle Libre Pro$125
- Omnipod$125
- Minimed 670G System$121
How this compares
$296,446 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 705 | $1,384,223 |
| JardianceEmpagliflozin | 130 | $206,053 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 114 | $168,254 |
| Tresiba Flextouch U-200Insulin Degludec | 118 | $145,722 |
| FarxigaDapagliflozin Propanediol | 92 | $126,324 |
| TrulicityDulaglutide | 65 | $109,659 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 122 | $80,036 |
| XyostedTestosterone Enanthate | 53 | $73,990 |
| Tresiba Flextouch U-100Insulin Degludec | 110 | $73,917 |
| RybelsusSemaglutide | 34 | $65,252 |
| JanuviaSitagliptin Phosphate | 44 | $55,395 |
| LyumjevInsulin Lispro-Aabc | 43 | $47,694 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 45 | $45,521 |
| FiaspInsulin Aspart (Niacinamide) | 31 | $45,488 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 30 | $42,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $257,148 | $1,512,228815 claims |
| Lilly USA, LLCTrulicity, Lyumjev, Mounjaro, Humalog | $282 | $219,447206 claims |
| Boehringer IngelheimJardiance | $281 | $206,053130 claims |
| AstraZenecaFarxiga | $491 | $126,32492 claims |
| Johnson & JohnsonInvokana | $6,826 | $33,98526 claims |
| AbbVieSynthroid | $6,198 | $17,186160 claims |
| Amneal Pharmaceuticals LLCUnithroid | $257 | $4,99984 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Turnersville
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Stanislav GoykhmanLyndhurst$278K
- Matthew CorcoranEgg Harbor Township$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.